

BME - GROWTH
Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 22nd May 2024

## COMMUNICATION- OTHER RELEVANT INFORMATION - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17<sup>th</sup> March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter "FacePhi" or "the Company", interchangeably).

Last 13<sup>th</sup> of May, the Company delivered a Privileged Information informing about the addendum granted with Nice & Green agreeing to cancel new convertible bonds issuance. It was also confirmed that conversion conditions for the tranches already issued, remained.

In light of the above, Nice & Green notified to the Company and exercised its right to convert 120 Notes (2<sup>nd</sup> and 3<sup>rd</sup> Tranche 2024) for a conversion amount of 1.200,000 euros. As a result of the foregoing, the Company will grant a capital increase title deed to cover the conversion of that said Notes. The 701.303 new shares of the Company are issued with an issuing price of 1,7111 euros (issue premium 1,6711 euros plus 0.04 euros of nominal value).

After this capital increase has been granted, the share capital will set at the sum of € 903.574,04 represented by 22.589.351 shares of € 0.04 nominal value each, of the same class, equal, cumulative and indivisible.

Following the exercise of these 120 convertible bonds, series "2<sup>nd</sup> & 3<sup>rd</sup> Tranche 2024" have been redeemed, remaining 60 bonds to be converted corresponding to the 4<sup>th</sup> tranche of 2024

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary. Sincerely,

Javier Mira Miró

**Chairman of the Board of Directors**